Cargando…

Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis

BACKGROUND: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. Expert consensus recommends a risk‐based approach to guide prophylactic anticoagulation to prevent VTE in ambulatory patients with cancer receiving chemotherapy. However, oncology practice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Karlyn A., Molsberry, Rebecca, Khan, Sadiya S., Linder, Jeffrey A., Cameron, Kenzie A., Benson, Al
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles ‐ Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590270/ https://www.ncbi.nlm.nih.gov/pubmed/33134786 http://dx.doi.org/10.1002/rth2.12431

Ejemplares similares

Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement
por: Jameson, S. S., et al.
Publicado: (2014)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Overall and abdominal obesity in relation to venous thromboembolism
por: Yuan, Shuai, et al.
Publicado: (2020)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients
por: Davila, Jennifer, et al.
Publicado: (2022)

Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
por: Moustafa, Farès, et al.
Publicado: (2017)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
por: Raskob, Gary E., et al.
Publicado: (2022)

Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2022)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism
por: Carney, Brian J., et al.
Publicado: (2020)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Venous thromboembolism prevention in cancer care: implementation strategies to address underuse
por: Martin, Karlyn A., et al.
Publicado: (2023)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis
por: Castellucci, L A, et al.
Publicado: (2014)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

Genetic risk and incident venous thromboembolism in middle‐aged and older adults following COVID‐19 vaccination
por: Xie, Junqing, et al.
Publicado: (2022)

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
por: Frischmuth, Tobias, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies
por: Haas, Sylvia, et al.
Publicado: (2021)

Hematocrit and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2020)

Resting heart rate and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2019)

Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
por: Ward, Joey, et al.
Publicado: (2023)

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Planquette, Benjamin, et al.
Publicado: (2019)

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
por: Hill, Jason B., et al.
Publicado: (2020)

RNA expression and risk of venous thromboembolism in lung cancer
por: Sussman, Tamara A., et al.
Publicado: (2019)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

A prospective study of migraine history and venous thromboembolism in older adults
por: Folsom, Aaron R., et al.
Publicado: (2019)

Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy
por: Overvad, Thure Filskov, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sll1pchr0ddkaei7bk0sfiugep